subject: Wang Peng: Innovation Complex unabated ethnic Chinese Dream - National Medical - pharmaceutical industries [print this page] Peng graduated from Tokyo University of Pharmacy, the drug has over 25 years the background of huge overseas research study in the United States, New Jersey Cross Pharmacy Schering-Plough Research Institute Inc. served as postdoctoral researchers, senior scientists, Deputy Chief Scientist, Chief Scientist, Senior Principal Scientist and Senior Scientist; in March 2008 returned to join WuXi PharmaTech As vice president of biological research and development; this year in May joined the precursor to medicine, to become chief scientific officer. As early as 8 years ago, he began to herald Pharmaceutical CEO Ren Jinsheng and senior vice president, research into the president of Yin Xiao Medicine R & D enterprise, while the real return to promote their domestic and select the harbinger of the reason is the same with Ren Jinsheng strong feeling of national pharmaceutical innovation. Served as co-head of Schering-Plough R & D team or the biological leader, his team has developed for the Schering-Plough clinical development of drug candidates, 9 of which are now in clinical stage 1, 3 in clinical stage , 2 in clinical stage , stage of development. His multinational pharmaceutical companies for many years in foreign service, has been "to the Chinese people to build their own national medicine." Returned to join WuXi PharmaTech, the Peng is still feeling for the multi-national enterprises, and Ren Jinsheng to herald the establishment of "China's innovation leader in drug development," the goal, and Wang Peng's National Medical Complex is not seeking and innovation co. He decided to leave work just over a year, WuXi PharmaTech, switched to herald. Although less than six months into the herald But those who herald Medicine Chief Scientific Officer of Wang Peng Yin Xiao Jin has set a strategic plan together. Currently, he is not busy digging more drug research with overseas backgrounds are more foreign pharmaceutical companies introduced a new model of drug research, strongly promote the harbinger of international Cooperation Levels of early fruit. He is very confident that all this is paid off in the near future. Dialogue Reporter: Do you think the greatest herald and WuXi PharmaTech What is the difference? Or maybe the question can be extended to domestic and transnational aspects of drug research and pharmaceutical companies the main difference? Peng: WuXi PharmaTech's main business is CRO, although it is China's leading CRO, but the lack of independent intellectual property rights of the drugs. Herald Although it is not the largest pharmaceutical companies in China, but with their own R & D capability and independent intellectual property rights of medicines, which makes the precursor and foreign pharmaceutical companies are very similar, but not as diversified as some large pharmaceutical companies, business bulky. It can be said is the most like a precursor to foreign pharmaceutical companies in the company. We dare not say that the industry's first, but the future will try to be the first. Herald is reshaping the strategic R & D personnel to create the next step in international business strategy focused on are: to carry out a series of international cooperation, development of foreign products, and its introduction of China; strengthen the domestic market, drug development, increase investment in scientific research institutions to further strengthen cooperation, open up lines of international cooperation. Reporter: WuXi PharmaTech and the precursor to all NYSE listed company in the industry seem to be very competitive, why you chose the former homes harbinger? Peng: this question Why should I return home about. In the United States for nearly 20 years, research in medicine abroad for 25 years, felt the potential of the Chinese pharmaceutical market has been greater than the world market, a good medicine in China than in Europe and the United States less obvious, even so, prices are also very expensive, China good medicine, the demand for new drugs is far greater than Europe and the United States. Second, China has huge space for development, personal career development as a great space. WuXi PharmaTech first reason is because its customers are overseas enterprises, culture and habits not suited to the place I did not. However, there more than a year, feeling CRO is still working in a foreign enterprise, foreign companies are still "hand" and laboratories. This is my original intention to return "to do national medicine" contrary to, so I decided to quit to the herald. Reporter: What is the precursor to the direction of R & D? Peng: product structure, we are now generic drugs still account for 50% of profits, but simply from the original small-molecule drugs that turned into the "protein drugs"?? Macromolecular drugs (such as "en") for the study At present there are plans to increase investment in large molecules of biological drug efforts, and has been extended through the acquisition of access to vaccines in the field of biological applications.
Wang Peng: Innovation Complex unabated ethnic Chinese Dream - National Medical - pharmaceutical industries
